SCHEMBL5160073

SCHEMBL5160073

COC(=O)CCc1cnc(N2CCC[C@@H]2OC(C)C(=O)OCc2ccccc2)o1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.39
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
PREP P48147 3/20 0.36
GRIN2B Q13224 5/20 0.35
ACE2 Q9BYF1 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 2/20 0.35
ALDH1A1 P00352 1/20 0.35
TSHR P16473 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
FKBP1A P62942 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160179 0.77 HRH3 (0.35) SMN1; SMN2CYP11B1CYP11B2ALDH1A1TSHR
SCHEMBL5160189 0.72 FKBP1A (0.46) HTTPREPACE2CYP3A4ALDH1A1
SCHEMBL5160862 0.72 CYP11B1 (0.38) HTTNPC1RAB9ASMN1; SMN2CYP11B1
SCHEMBL5162622 0.69 HRH3 (0.33) SMN1; SMN2ALDH1A1TDP1
SCHEMBL6174777 0.66 ATM (0.41) HTTSMN1; SMN2L3MBTL1TDP1
Hydrochloric Acid SCHEMBL5160752 0.65 HRH3 (0.37) SMN1; SMN2ALDH1A1TDP1
SCHEMBL5161814 0.64 AOC3 (0.39)
SCHEMBL23034568 0.63 CYP3A4 (0.47) CYP1A2CYP3A4ALDH1A1TSHRL3MBTL1
SCHEMBL5160202 0.63 HTT (0.47) HTTNPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL26447162 0.63 ALDH1A1 (0.50) HTTALDH1A1L3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070232601-A1 Vla-4 Inhibitor DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-10-04 US disclosed
EP-1757602-A1 VLA-4 INHIBITOR DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232601-A1 Vla-4 Inhibitor VCAM1, ITGB4, ITGA4 HTT 3765/4885NPC1 907/4885RAB9A 1194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.